Tau degradation in Alzheimer's disease: Mechanisms and therapeutic opportunities
Alzheimer's & Dementia · 2025-03 · 21 (3)
DOI: 10.1002/alz.70048 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, online erschienen am 20.03.2025. Verfasst von Lisha Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden. Hauptthemen laut MEDLINE: Alzheimer Disease, tau Proteins, Proteolysis. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Private Initiative "Innovative ways to fight Alzheimer´s disease Leif Lundblad Family and others", Strategic Research Program in Neuroscience (StratNeuro) funding for postdoctoral researchers at Karolinska Institutet, Stiftelsen för Gamla Tjänarinnor.
Themen: Demenz
Abstract (Originalsprache)
In Alzheimer's disease (AD), tau undergoes abnormal post‐translational modifications and aggregations. Impaired intracellular degradation pathways further exacerbate the accumulation of pathological tau. A new strategy – targeted protein degradation – recently emerged as a modality in drug discovery where bifunctional molecules bring the target protein close to the degradation machinery to promote clearance. Since 2016, this strategy has been applied to tau pathologies and attracted broad interest in academia and the pharmaceutical industry. However, a systematic review of recent studies on tau degradation mechanisms is lacking. Here we review tau degradation mechanisms (the ubiquitin–proteasome system and the autophagy–lysosome pathway), their dysfunction in AD, and tau‐targeted degraders, such as proteolysis‐targeting chimeras and autophagy‐targeting chimeras. We emphasize the need for a continuous exploration of tau degradation mechanisms and provide a future perspective for developing tau‐targeted degraders, encouraging researchers to work on new treatment options for AD patients. Highlights Post‐translational modifications, aggregation, and mutations affect tau degradation. A vicious circle exists between impaired degradation pathways and tau pathologies. Ubiquitin plays an important role in complex degradation pathways. Tau‐targeted degraders provide promising strategies for novel AD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.
- Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi, India.
- Theme Inflammation and Aging, Karolinska University Hospital, Huddinge, Sweden.
Förderung
- Private Initiative "Innovative ways to fight Alzheimer´s disease Leif Lundblad Family and others"
- Strategic Research Program in Neuroscience (StratNeuro) funding for postdoctoral researchers at Karolinska Institutet
- Stiftelsen för Gamla Tjänarinnor
- Gun och Bertil Stohnes Stiftelse
- Åhlén-stiftelsen
- Tore Nilsons Stiftelse för Medicinsk Forskning
- Hjärnfonden
- Vetenskapsrådet
Zitieren
APA
Wang, L., Sooram, B., Kumar, R., Schedin-Weiss, S., Tjernberg, L. O., & Winblad, B. (2025). Tau degradation in Alzheimer's disease: Mechanisms and therapeutic opportunities. Alzheimer's & Dementia, 21(3). https://doi.org/10.1002/alz.70048
Vancouver
Wang L, Sooram B, Kumar R, Schedin-Weiss S, Tjernberg LO, Winblad B. Tau degradation in Alzheimer's disease: Mechanisms and therapeutic opportunities. Alzheimer's & Dementia. 2025;21(3). doi:10.1002/alz.70048
BibTeX
@article{Wang2025,
author = {Wang, Lisha and Sooram, Banesh and Kumar, Rajnish and Schedin-Weiss, Sophia and Tjernberg, Lars O and Winblad, Bengt},
title = {Tau degradation in Alzheimer's disease: Mechanisms and therapeutic opportunities},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {3},
doi = {10.1002/alz.70048}
}
EUVIMED